Q1 EPS Estimate for Soleno Therapeutics Decreased by Analyst

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Stock analysts at Lifesci Capital reduced their Q1 2025 EPS estimates for shares of Soleno Therapeutics in a research note issued on Thursday, March 27th. Lifesci Capital analyst M. Belghiti now expects that the company will earn ($1.46) per share for the quarter, down from their previous forecast of ($1.43). Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Lifesci Capital also issued estimates for Soleno Therapeutics’ Q2 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($0.63) EPS, FY2025 earnings at ($2.84) EPS, Q1 2026 earnings at ($1.20) EPS, Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at $0.25 EPS, Q4 2026 earnings at $0.32 EPS and FY2026 earnings at ($0.47) EPS.

Several other equities analysts have also recently issued reports on the company. Laidlaw raised their price target on Soleno Therapeutics from $75.00 to $105.00 and gave the company a “buy” rating in a report on Thursday. Stifel Nicolaus upped their target price on shares of Soleno Therapeutics from $74.00 to $108.00 and gave the company a “buy” rating in a research report on Friday. Cantor Fitzgerald lifted their price target on shares of Soleno Therapeutics from $67.00 to $123.00 and gave the stock an “overweight” rating in a research report on Thursday. Robert W. Baird increased their price objective on shares of Soleno Therapeutics from $72.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $70.00 target price on shares of Soleno Therapeutics in a report on Monday, March 3rd. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $94.57.

Soleno Therapeutics Stock Performance

Shares of SLNO opened at $71.99 on Monday. The business’s fifty day moving average price is $48.94 and its two-hundred day moving average price is $50.08. The firm has a market capitalization of $3.30 billion, a price-to-earnings ratio of -21.68 and a beta of -1.70. Soleno Therapeutics has a 52 week low of $36.61 and a 52 week high of $73.97.

Soleno Therapeutics (NASDAQ:SLNO) last announced its earnings results on Wednesday, March 5th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.41).

Insiders Place Their Bets

In other Soleno Therapeutics news, CEO Bhatnagar Anish sold 10,937 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $45.41, for a total value of $496,649.17. Following the completion of the sale, the chief executive officer now directly owns 708,616 shares in the company, valued at $32,178,252.56. This represents a 1.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James H. Mackaness sold 4,083 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $45.41, for a total value of $185,409.03. Following the sale, the chief financial officer now directly owns 115,089 shares in the company, valued at approximately $5,226,191.49. This represents a 3.43 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 17,360 shares of company stock worth $790,119. Company insiders own 12.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in SLNO. AlphaQuest LLC grew its stake in shares of Soleno Therapeutics by 1,154.4% in the fourth quarter. AlphaQuest LLC now owns 715 shares of the company’s stock valued at $32,000 after buying an additional 658 shares in the last quarter. US Bancorp DE acquired a new stake in Soleno Therapeutics in the fourth quarter valued at $34,000. Avanza Fonder AB bought a new position in shares of Soleno Therapeutics in the 4th quarter valued at about $76,000. Springhill Fund Asset Management HK Co Ltd bought a new position in shares of Soleno Therapeutics in the 4th quarter valued at about $81,000. Finally, Avior Wealth Management LLC acquired a new position in shares of Soleno Therapeutics during the 4th quarter worth about $89,000. Institutional investors and hedge funds own 97.42% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.